Real-World Comparison Favors Odronextamab in R/R Follicular LymphomaByAndrea Eleazar, MHSApril 23rd 2026
Tazemetostat Withdrawn From All Trials and Markets Due to Safety ConcernsByPaige BrittMarch 10th 2026
Pirtobrutinib Yields Promising Efficacy, Safety in R/R Follicular LymphomaByPaige BrittDecember 22nd 2025